Table 4:

Adverse events reported in participants during the study, by study group

	nOPV2 only group (n=264)	nOPV2 plus bOPV group (n=265)	bOPV only group (n=266)
Any adverse event	24 (9%)	17 (6%)	20 (8%)
Any serious adverse event	5 (2%)	4 (2%)	6 (2%)
Unsolicited adverse events
Any	17 (6%)	16 (6%)	16 (6%)
Acute respiratory infections	6 (2%)	8 (3%)	7 (3%)
Acute diarrhoea and gastroenteritis	4 (2%)	4 (2%)	3 (1%)
Pneumonia	5 (2%)	3 (1%)	2 (1%)
Death, SIDS	1 (<1%)	1 (<1%)	1 (<1%)
Cardiomyopathy	0	0	1 (<1%)
Dengue	0	0	1 (<1%)
Fever	0	0	1 (<1%)
Malnutrition	0	1 (<1%)	0
Oral thrush	1 (<1%)	0	0
Solicited adverse events
Any	7 (3%)	1 (<1%)	5 (2%)
Fever	5 (2%)	1 (<1%)	4 (2%)
Abnormal crying	0	1 (<1%)	1 (<1%)
Vomiting	1 (<1%)	0	1 (<1%)
Poor feeding	1 (<1%)	0	0
Other (diarrhoea)	1 (<1%)	0	0
Irritability	0	0	0
Drowsiness	0	0	0

Data are n (%). bOPV=bivalent oral poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2. SIDS=sudden infant death syndrome.